【摘要】 新型口服抗凝药物艾多沙班作为直接Xa因子抑制剂，具有口服吸收快、药物和食物相互作用小、无需常规监测凝血指标且具有良好的耐受性、安全性及依从性等优势。尽管上市时间较晚，但其在心血管疾病的临床应用越来越广泛，现将艾多沙班在心血管疾病中的研究进展做一综述。更多还原

【Abstract】 Edoxaban, a new oral anticoagulant, as a direct factor Xa inhibitor, has the advantages of rapid oral absorption, small interaction between drug and food, no routine monitoring of coagulation indicators, good tolerance, safety and compliance.Although it has been on the market late, it is more and more widely used in the clinical practice of cardiovascular disease.This article reviews the research progress of edoxaban in cardiovascular disease.更多还原